Exelixis Inc (EXEL) 6.05 $EXEL
Exelixis Meteoric Rise on Positive Kidney Cancer Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 21, 5:40PM CDT
Exelixis' (EXEL) Cometriq scores in a late-stage study (METEOR) in patients with metastatic renal cell carcinoma.
EBIO: 2.95 (-0.04), AMAG: 72.59 (-1.83), NVS: 103.71 (-2.41), EXEL: 6.05 (+0.17)
Chesapeake Energy and IBM are big market movers
AP - Tue Jul 21, 3:24PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
HAS: 80.42 (-2.73), HOG: 57.67 (+2.73), CNX: 17.55 (+0.89), LMT: 203.15 (-1.98), EBAY: 28.60 (+0.03), LII: 115.71 (-0.68), CF: 63.94 (-1.06), CHK: 9.29 (-0.98), HAL: 41.86 (+1.14), CZR: 8.02 (+1.47), VZ: 46.97 (-1.13), EXEL: 6.05 (+0.17)
Exelixis Launches Proposed Public Offering of Common Stock
Business Wire - Tue Jul 21, 3:01PM CDT
Exelixis, Inc. (Nasdaq:EXEL) today announced that it plans to offer, subject to market and other conditions, 20,000,000 shares of its common stock in an underwritten public offering. The company expects to grant the underwriters a 30-day option to purchase up to an additional 3,000,000 shares of common stock in connection with the offering. All of the shares of common stock in the offering will be sold by Exelixis.
EXEL: 6.05 (+0.17)
Ewing Sarcoma Pipeline Report 2015 - 15 Companies & 23 Drug Profiles
M2 - Tue Jul 21, 10:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z9h72l/ewing_sarcoma) has announced the addition of the "Ewing Sarcoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ewing Sarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ewing Sarcoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 3B Pharmaceuticals GmbH - Amgen Inc. - Cebiotex, S.L. - EntreChem, S.L. - Exelixis, Inc. - Gradalis Inc. - Kolltan Pharmaceuticals, Inc. - Merck & Co., Inc. - Merrimack Pharmaceuticals, Inc. - Novartis AG - Oncomatrix, S.L. - Recombio S.L - Shionogi & Co., Ltd. - Sigma-Tau S.p.A. - Tesaro, Inc. Drug Profiles - 3BP-227 - cabozantinib s-malate - cancer vaccine - CEB-01 - celyvir - dactinomycin next generation - Dendritic Cell Therapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - EC-8042 - EC-8105 - everolimus - ganitumab - irinotecan sucrosofate liposomal - KIT-SG3227 - Monoclonal Antibody Conjugated for Ewing Sarcoma - Monoclonal Antibody to Inhibit GD2 for Oncology - MTX2-NIG - niraparib - pazopanib hydrochloride - pembrolizumab - racotumomab - S-588410 - SP-2509 - SST-0001 For more information visit http://www.researchandmarkets.com/research/z9...ng_sarcoma
MACK: 9.84 (-0.41), TSRO: 64.01 (-1.74), MRK: 58.67 (-0.33), AMGN: 163.70 (-0.64), NVS: 103.71 (-2.41), EXEL: 6.05 (+0.17)
Epithelial Ovarian Cancer Pipeline Review 2015 - 49 Companies & 69 Drug Profiles
M2 - Tue Jul 21, 10:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/snr9r3/epithelial) has announced the addition of the "Epithelial Ovarian Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Epithelial Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epithelial Ovarian Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Adaptimmune Limited - Amgen Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca PLC - Bayer AG - Bionomics Limited - BioNumerik Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - Celldex Therapeutics, Inc. - Celon Pharma Sp. z o.o. - Celsion Corporation - Cerulean Pharma, Inc. - Clovis Oncology, Inc. - Eli Lilly and Company - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Genentech, Inc. - Glycotope GmbH - ImmunoGen, Inc. - Immunotope, Inc. - Johnson & Johnson - MabVax Therapeutics Holdings, Inc. - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - NeoStem, Inc. - Novartis AG - Oasmia Pharmaceutical AB - OBI Pharma, Inc. - Oncobiologics, Inc. - Oncolytics Biotech Inc. - Onxeo SA - Otsuka Holdings Co., Ltd. - Pfizer Inc. - Pharma Mar, S.A. For more information visit http://www.researchandmarkets.com/research/snr9r3/epithelial
CLDX: 25.56 (-0.83), NBS: 2.25 (-0.09), CLSN: 2.45 (-0.02), JNJ: 100.34 (-0.03), ABBV: 70.54 (-0.26), EXEL: 6.05 (+0.17), ONCY: 0.66 (+0.02), CERU: 4.26 (-0.07), PFE: 35.14 (-0.10), IMGN: 18.65 (-0.23), AMGN: 163.70 (-0.64), LLY: 85.57 (-2.30), CLVS: 86.16 (+0.10), AZN: 67.64 (-0.21), MRK: 58.67 (-0.33), NVS: 103.71 (-2.41)
Progression Survival Benefit - BrokerBank Securities
PR Newswire - Tue Jul 21, 8:00AM CDT
Exelixis, Inc. (NASDAQ: EXEL) is a biotechnology company that develops and markets treatments for cancer. The company is in its development stage with one approved treatment. The two most advanced assets of the company are Cabozantinib, and Cobimetinib. Exelixis has five Phase III trials for various cancer treatments using Cabozantinib and Cobimetinib. On top of those, the company has numerous strategic partnerships with other drug companies, and multiple treatments in Phase II trials. Exelixis has a huge pipeline of potential uses for its treatments.
EXEL: 6.05 (+0.17)
Potential Kidney Cancer Drugs Could Revolutionize Treatment
Todd Campbell, The Motley Fool - Motley Fool - Tue Jul 21, 7:05AM CDT
Source: Bristol-Myers Squibb. If treated early enough, kidney cancer patients have a five-year survival rate that is better than many other cancers. Unfortunately, though, treatment options are more limited, and survival rates less optimistic, for...
BMY: 68.87 (-1.10), EXEL: 6.05 (+0.17)
Soft Tissue Sarcoma Therapeutics Pipeline Report 2015 - Review of 46 Companies & 64 Drug Profiles
M2 - Tue Jul 21, 5:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vws7wm/soft_tissue) has announced the addition of the "Soft Tissue Sarcoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Soft Tissue Sarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Soft Tissue Sarcoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - A. Menarini Industrie Farmaceutiche Riunite Srl - Advanced Proteome Therapeutics Corporation - Advenchen Laboratories, LLC - Altor BioScience Corporation - Amgen Inc. - Bayer AG - Bellicum Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - CASI Pharmaceuticals Inc. - Celgene Corporation - Cellectar Biosciences, Inc. - CytRx Corporation - Daiichi Sankyo Company, Limited - Eisai Co., Ltd. - Eli Lilly and Company - EpiZyme, Inc. - Exelixis, Inc. - Gem Pharmaceuticals, LLC - Immune Design Corp. - Karyopharm Therapeutics, Inc. - Loxo Oncology, Inc. - MedImmune, LLC - Merck & Co., Inc. - Merrimack Pharmaceuticals, Inc. - Mirati Therapeutics Inc. - MolMed S.p.A. - Morphotek, Inc. - Nanobiotix - Neotropix, Inc. - Novartis AG - Oncos Therapeutics Ltd. - Onxeo SA - Pfizer Inc. - Pharma Mar, S.A. - Plexxikon Inc. For more information visit http://www.researchandmarkets.com/research/vw...oft_tissue
LOXO: 17.44 (-0.35), CLRB: 3.55 (unch), IMDZ: 26.06 (-0.09), PFE: 35.14 (-0.10), AMGN: 163.70 (-0.64), LLY: 85.57 (-2.30), EPZM: 22.18 (+0.05), CASI: 1.66 (-0.02), MACK: 9.84 (-0.41), BLCM: 19.46 (-0.50), MRK: 58.67 (-0.33), CYTR: 3.04 (-0.76), MRTX: 31.46 (-1.51), NVS: 103.71 (-2.41), KPTI: 23.26 (-0.72), EXEL: 6.05 (+0.17), CELGZ: 2.19 (+0.01)
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Pipeline Review 2015 - Analysis of 35 Companies & 43 Drug Profiles
M2 - Tue Jul 21, 5:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6dp6kl/bile_duct_cancer) has announced the addition of the "Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 4SC AG - Agios Pharmaceuticals, Inc. - Ariad Pharmaceuticals, Inc. - ArQule, Inc. - Array BioPharma Inc. - Arrien Pharmaceuticals, LLC - AstraZeneca PLC - Bayer AG - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Celgene Corporation - CellAct Pharma GmbH - Concordia Healthcare Corp. - Cornerstone Pharmaceuticals, Inc. - Delcath Systems, Inc. - Eli Lilly and Company - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Komipharm International Co., Ltd. - Mebiopharm Co., Ltd. - Merck & Co., Inc. - Merrimack Pharmaceuticals, Inc. - Novartis AG - NuCana BioMed Limited - OncoTherapy Science, Inc. - Panacea Pharmaceuticals, Inc. - PCI Biotech AS - Pfizer Inc. - Provecs Medical GmbH - Sanofi - Senhwa Biosciences, Inc. - Spectrum Pharmaceuticals, Inc. - Threshold Pharmaceuticals, Inc. - VasGene Therapeutics, Inc. Drug Profiles - (dabrafenib mesylate trametinib dimethyl sulfoxide) - AG-120 - ARN-5032 - ARQ-087 - BBI-503 - BGJ-398 - binimetinib - cabozantinib s-malate - CAP-7.1 - CC-90007 - CPI-613 - dasatinib - DKN-01 - elpamotide - evofosfamide - gemcitabine hydrochloride - Im-01 - KML-001 - MBPY-005 - melphalan - merestinib - MK-2206 - NUC-1031 - OCVC-01 - paclitaxel albumin bound - PAN-622 - pembrolizumab - ponatinib hydrochloride - porfimer sodium For more information visit http://www.researchandmarkets.com/research/6d...uct_cancer
PFE: 35.14 (-0.10), ARQL: 1.84 (+0.01), SPPI: 7.27 (-0.14), LLY: 85.57 (-2.30), GSK: 42.63 (-0.39), BMY: 68.87 (-1.10), MACK: 9.84 (-0.41), MRK: 58.67 (-0.33), AZN: 67.64 (-0.21), AGIO: 114.09 (-1.02), DCTH: 0.49 (-0.03), NVS: 103.71 (-2.41), ARRY: 6.73 (-0.06), CELGZ: 2.19 (+0.01), CXRX: 80.55 (+1.70), EXEL: 6.05 (+0.17)
Endometrial Cancer Therapeutics Pipeline Review, H1 2015 - 35 Companies & 48 Drug Profiles
M2 - Tue Jul 21, 3:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/psfwd9/endometrial) has announced the addition of the "Endometrial Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Endometrial Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometrial Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acceleron Pharma, Inc. - Aeterna Zentaris Inc. - Ariad Pharmaceuticals, Inc. - Arno Therapeutics, Inc. - ArQule, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - BioMarin Pharmaceutical Inc. - Boehringer Ingelheim GmbH - Critical Outcome Technologies Inc. - Daiichi Sankyo Company, Limited - Eisai Co., Ltd. - Esperance Pharmaceuticals, Inc. - Exelixis, Inc. - Farmsintez - Galena Biopharma, Inc. - Genentech, Inc. - Genmab A/S - GlaxoSmithKline Plc - Gradalis Inc. - ImmunoGen, Inc. - Incyte Corporation - Karyopharm Therapeutics, Inc. - Merck & Co., Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - Novartis AG - OncoHoldings, Inc. - Oncothyreon Inc. - Otsuka Holdings Co., Ltd. - Pharma Mar, S.A. - Puma Biotechnology, Inc. - Sanofi - Scancell Holdings Plc - Shenogen Pharma Group Ltd. Drug Profiles - (ponatinib hydrochloride ridaforolimus) - ???Pb-TCMC-Trastuzumab - AEZS-125 - afuresertib hydrochloride trametinib dimethyl sulfoxide - ARQ-092 - AV-203 - AZD-2014 - AZD-5363 - buparlisib hydrochloride - cabozantinib s-malate - cancer vaccine - Cell Therapy for Oncology - CLR-457 - COTI-2 - cridanimod - dalantercept - EP-200 - epacadostat - everolimus - FROST-450 - GALE-301 - GDC-0927 - GSK-2636771 - HO-3867 - HuMax-TF-ADC - INCB-54828 - lenvatinib - lurbinectedin - mirvetuximab soravtansine - MK-2206 - Modi-1 - Monoclonal Antibody to Inhibit L1CAM for Ovarian and Endometrial Cancer - neratinib - nintedanib - onapristone ER For more information visit http://www.researchandmarkets.com/research/ps...ndometrial
BMRN: 143.79 (-5.34), ARQL: 1.84 (+0.01), GALE: 1.74 (+0.01), EXEL: 6.05 (+0.17), XLRN: 30.79 (-1.79), INCY: 113.87 (-1.90), IMGN: 18.65 (-0.23), GSK: 42.63 (-0.39), ONTY: 3.62 (-0.04), AZN: 67.64 (-0.21), MRK: 58.67 (-0.33), AVEO: 1.68 (+0.06), PBYI: 99.72 (-3.54), KPTI: 23.26 (-0.72), NVS: 103.71 (-2.41)
Bristol-Myers: kidney drug win
at Investor's Business Daily - Mon Jul 20, 5:41PM CDT
The big pharma said that its Opdivo scored another win Mon. as a late-stage trial in kidney cancer was stopped early because it had already hit its endpoint. The trial compared Opdivo with everolimus, better known as Novartis' (NVS) Afinitor, in...
BMY: 68.87 (-1.10), EXEL: 6.05 (+0.17), NVS: 103.71 (-2.41)
Market Wrap: A Tech-Led Tick Higher
at The Street - Mon Jul 20, 3:45PM CDT
But energy and materials names, crude oil and gold all dropped.
HOG: 57.67 (+2.73), IBM: 163.07 (-10.15), UTX: 102.71 (-7.77), SUNE: 29.37 (-2.29), KKR: 24.20 (+0.44), VSLR: 15.85 (+0.10), VZ: 46.97 (-1.13), BHI: 60.64 (+1.18), EXEL: 6.05 (+0.17)
Exelixis' Meteroric Rise From the Ashes
Brian Orelli, The Motley Fool - Motley Fool - Mon Jul 20, 1:33PM CDT
Score one for tenacity. Exelixis is up almost 50% today after releasing positive results from its phase 3 trial, dubbed Meteor, testing its drug Cometriq in patients with kidney cancer. It's been a long road to get here. Like many...
EXEL: 6.05 (+0.17)
Bristol-Myers, Exelixis Drugs Score Vs. Kidney Cancer
at Investor's Business Daily - Mon Jul 20, 9:50AM CDT
Big pharma Bristol-Myers Squibb's (BMY) new drug Opdivo scored another win Monday, as a late-stage trial in kidney cancer was stopped early because it had already hit its endpoint. Small biotech Exelixis (EXEL) also reported success in a...
BMY: 68.87 (-1.10), NVS: 103.71 (-2.41), EXEL: 6.05 (+0.17)
Why Exelixis, Inc.'s Stock Skyrocketed Today
George Budwell, The Motley Fool - Motley Fool - Mon Jul 20, 9:46AM CDT
What's happening : Shares of Exelixis shot up by nearly 50% today on heavy volume after the company announced that its flagship cancer drug Cometriq (cabozantinib) met its primary endpoint of improving progression-free survival for renal cell...
EXEL: 6.05 (+0.17)
BUYINS.NET: EXEL SqueezeTrigger Price is $4.97. There is $285,011,222 That Short Sellers Still Need To Cover.
M2 - Mon Jul 20, 9:24AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring Exelixis Inc (NASDAQ:EXEL) in real time and just received an alert that EXEL is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 49309900 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $4.97. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
EXEL: 6.05 (+0.17)
Exelixis Scores Much-Needed Kidney Cancer Study Win to Boost Drug Sales
at The Street - Mon Jul 20, 6:01AM CDT
Exelixis plans to seek expanded approval for Cometriq in kidney cancer in early 2016.
NVS: 103.71 (-2.41), EXEL: 6.05 (+0.17)
Exelixis Announces Positive Top-Line Results from METEOR, the Phase 3 Pivotal Trial of Cabozantinib versus Everolimus in Patients with Metastatic Renal Cell Carcinoma
Business Wire - Mon Jul 20, 6:00AM CDT
--- Cabozantinib Reduced the Risk of Disease Progression or Death by 42%; Hazard Ratio = 0.58, (p < 0.0001) Compared to Everolimus -
EXEL: 6.05 (+0.17)
3 Biotech Stocks 50% (or More) Off Their 5-Year Highs That Could Double
Sean Williams, The Motley Fool - Motley Fool - Thu Jul 16, 8:01AM CDT
Source: Food and Drug Administration via Facebook. If there is such a thing as a poster child for volatility in the stock market, the biotech sector would likely take top honors. Biotech stocks are unique. While stocks in other sectors are...
THLD: 4.26 (-0.01), XOMA: 4.39 (-0.13), EXEL: 6.05 (+0.17)
Exelixis Appoints Chris Senner as Executive Vice President and Chief Financial Officer
Business Wire - Wed Jul 15, 7:00PM CDT
Exelixis, Inc. (NASDAQ:EXEL) today announced the appointment of Christopher J. Senner as Executive Vice President and Chief Financial Officer. Mr. Senner has nearly 25 years of experience in biopharmaceutical finance, including deep expertise in global financial operations and controls, strategic planning and analysis, supply chain finance and business development. He joins Exelixis after five years at Gilead Sciences, where he served as Vice President, Corporate Finance. He previously spent eighteen years at Wyeth in a variety of financial roles with increasing responsibility for many of the company's divisions and regions. He joins Exelixis in advance of several potentially transformational milestones anticipated this year, including top-line results from the METEOR phase 3 pivotal trial and the potential U.S. and EU regulatory approvals of cobimetinib, a compound discovered by Exelixis and then licensed to Genentech for further development and commercialization.
EXEL: 6.05 (+0.17)
Exelixis Meteoric Rise on Positive Kidney Cancer Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 21, 5:40PM CDT
Exelixis' (EXEL) Cometriq scores in a late-stage study (METEOR) in patients with metastatic renal cell carcinoma.
EBIO: 2.95 (-0.04), AMAG: 72.59 (-1.83), NVS: 103.71 (-2.41), EXEL: 6.05 (+0.17)
Chesapeake Energy and IBM are big market movers
AP - Tue Jul 21, 3:24PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
HAS: 80.42 (-2.73), HOG: 57.67 (+2.73), CNX: 17.55 (+0.89), LMT: 203.15 (-1.98), EBAY: 28.60 (+0.03), LII: 115.71 (-0.68), CF: 63.94 (-1.06), CHK: 9.29 (-0.98), HAL: 41.86 (+1.14), CZR: 8.02 (+1.47), VZ: 46.97 (-1.13), EXEL: 6.05 (+0.17)
Exelixis Launches Proposed Public Offering of Common Stock
Business Wire - Tue Jul 21, 3:01PM CDT
Exelixis, Inc. (Nasdaq:EXEL) today announced that it plans to offer, subject to market and other conditions, 20,000,000 shares of its common stock in an underwritten public offering. The company expects to grant the underwriters a 30-day option to purchase up to an additional 3,000,000 shares of common stock in connection with the offering. All of the shares of common stock in the offering will be sold by Exelixis.
EXEL: 6.05 (+0.17)
Ewing Sarcoma Pipeline Report 2015 - 15 Companies & 23 Drug Profiles
M2 - Tue Jul 21, 10:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z9h72l/ewing_sarcoma) has announced the addition of the "Ewing Sarcoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ewing Sarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ewing Sarcoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 3B Pharmaceuticals GmbH - Amgen Inc. - Cebiotex, S.L. - EntreChem, S.L. - Exelixis, Inc. - Gradalis Inc. - Kolltan Pharmaceuticals, Inc. - Merck & Co., Inc. - Merrimack Pharmaceuticals, Inc. - Novartis AG - Oncomatrix, S.L. - Recombio S.L - Shionogi & Co., Ltd. - Sigma-Tau S.p.A. - Tesaro, Inc. Drug Profiles - 3BP-227 - cabozantinib s-malate - cancer vaccine - CEB-01 - celyvir - dactinomycin next generation - Dendritic Cell Therapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - EC-8042 - EC-8105 - everolimus - ganitumab - irinotecan sucrosofate liposomal - KIT-SG3227 - Monoclonal Antibody Conjugated for Ewing Sarcoma - Monoclonal Antibody to Inhibit GD2 for Oncology - MTX2-NIG - niraparib - pazopanib hydrochloride - pembrolizumab - racotumomab - S-588410 - SP-2509 - SST-0001 For more information visit http://www.researchandmarkets.com/research/z9...ng_sarcoma
MACK: 9.84 (-0.41), TSRO: 64.01 (-1.74), MRK: 58.67 (-0.33), AMGN: 163.70 (-0.64), NVS: 103.71 (-2.41), EXEL: 6.05 (+0.17)
Epithelial Ovarian Cancer Pipeline Review 2015 - 49 Companies & 69 Drug Profiles
M2 - Tue Jul 21, 10:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/snr9r3/epithelial) has announced the addition of the "Epithelial Ovarian Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Epithelial Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epithelial Ovarian Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Adaptimmune Limited - Amgen Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca PLC - Bayer AG - Bionomics Limited - BioNumerik Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - Celldex Therapeutics, Inc. - Celon Pharma Sp. z o.o. - Celsion Corporation - Cerulean Pharma, Inc. - Clovis Oncology, Inc. - Eli Lilly and Company - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Genentech, Inc. - Glycotope GmbH - ImmunoGen, Inc. - Immunotope, Inc. - Johnson & Johnson - MabVax Therapeutics Holdings, Inc. - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - NeoStem, Inc. - Novartis AG - Oasmia Pharmaceutical AB - OBI Pharma, Inc. - Oncobiologics, Inc. - Oncolytics Biotech Inc. - Onxeo SA - Otsuka Holdings Co., Ltd. - Pfizer Inc. - Pharma Mar, S.A. For more information visit http://www.researchandmarkets.com/research/snr9r3/epithelial
CLDX: 25.56 (-0.83), NBS: 2.25 (-0.09), CLSN: 2.45 (-0.02), JNJ: 100.34 (-0.03), ABBV: 70.54 (-0.26), EXEL: 6.05 (+0.17), ONCY: 0.66 (+0.02), CERU: 4.26 (-0.07), PFE: 35.14 (-0.10), IMGN: 18.65 (-0.23), AMGN: 163.70 (-0.64), LLY: 85.57 (-2.30), CLVS: 86.16 (+0.10), AZN: 67.64 (-0.21), MRK: 58.67 (-0.33), NVS: 103.71 (-2.41)
Progression Survival Benefit - BrokerBank Securities
PR Newswire - Tue Jul 21, 8:00AM CDT
Exelixis, Inc. (NASDAQ: EXEL) is a biotechnology company that develops and markets treatments for cancer. The company is in its development stage with one approved treatment. The two most advanced assets of the company are Cabozantinib, and Cobimetinib. Exelixis has five Phase III trials for various cancer treatments using Cabozantinib and Cobimetinib. On top of those, the company has numerous strategic partnerships with other drug companies, and multiple treatments in Phase II trials. Exelixis has a huge pipeline of potential uses for its treatments.
EXEL: 6.05 (+0.17)
Potential Kidney Cancer Drugs Could Revolutionize Treatment
Todd Campbell, The Motley Fool - Motley Fool - Tue Jul 21, 7:05AM CDT
Source: Bristol-Myers Squibb. If treated early enough, kidney cancer patients have a five-year survival rate that is better than many other cancers. Unfortunately, though, treatment options are more limited, and survival rates less optimistic, for...
BMY: 68.87 (-1.10), EXEL: 6.05 (+0.17)
Soft Tissue Sarcoma Therapeutics Pipeline Report 2015 - Review of 46 Companies & 64 Drug Profiles
M2 - Tue Jul 21, 5:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vws7wm/soft_tissue) has announced the addition of the "Soft Tissue Sarcoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Soft Tissue Sarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Soft Tissue Sarcoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - A. Menarini Industrie Farmaceutiche Riunite Srl - Advanced Proteome Therapeutics Corporation - Advenchen Laboratories, LLC - Altor BioScience Corporation - Amgen Inc. - Bayer AG - Bellicum Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - CASI Pharmaceuticals Inc. - Celgene Corporation - Cellectar Biosciences, Inc. - CytRx Corporation - Daiichi Sankyo Company, Limited - Eisai Co., Ltd. - Eli Lilly and Company - EpiZyme, Inc. - Exelixis, Inc. - Gem Pharmaceuticals, LLC - Immune Design Corp. - Karyopharm Therapeutics, Inc. - Loxo Oncology, Inc. - MedImmune, LLC - Merck & Co., Inc. - Merrimack Pharmaceuticals, Inc. - Mirati Therapeutics Inc. - MolMed S.p.A. - Morphotek, Inc. - Nanobiotix - Neotropix, Inc. - Novartis AG - Oncos Therapeutics Ltd. - Onxeo SA - Pfizer Inc. - Pharma Mar, S.A. - Plexxikon Inc. For more information visit http://www.researchandmarkets.com/research/vw...oft_tissue
LOXO: 17.44 (-0.35), CLRB: 3.55 (unch), IMDZ: 26.06 (-0.09), PFE: 35.14 (-0.10), AMGN: 163.70 (-0.64), LLY: 85.57 (-2.30), EPZM: 22.18 (+0.05), CASI: 1.66 (-0.02), MACK: 9.84 (-0.41), BLCM: 19.46 (-0.50), MRK: 58.67 (-0.33), CYTR: 3.04 (-0.76), MRTX: 31.46 (-1.51), NVS: 103.71 (-2.41), KPTI: 23.26 (-0.72), EXEL: 6.05 (+0.17), CELGZ: 2.19 (+0.01)
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Pipeline Review 2015 - Analysis of 35 Companies & 43 Drug Profiles
M2 - Tue Jul 21, 5:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6dp6kl/bile_duct_cancer) has announced the addition of the "Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 4SC AG - Agios Pharmaceuticals, Inc. - Ariad Pharmaceuticals, Inc. - ArQule, Inc. - Array BioPharma Inc. - Arrien Pharmaceuticals, LLC - AstraZeneca PLC - Bayer AG - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Celgene Corporation - CellAct Pharma GmbH - Concordia Healthcare Corp. - Cornerstone Pharmaceuticals, Inc. - Delcath Systems, Inc. - Eli Lilly and Company - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Komipharm International Co., Ltd. - Mebiopharm Co., Ltd. - Merck & Co., Inc. - Merrimack Pharmaceuticals, Inc. - Novartis AG - NuCana BioMed Limited - OncoTherapy Science, Inc. - Panacea Pharmaceuticals, Inc. - PCI Biotech AS - Pfizer Inc. - Provecs Medical GmbH - Sanofi - Senhwa Biosciences, Inc. - Spectrum Pharmaceuticals, Inc. - Threshold Pharmaceuticals, Inc. - VasGene Therapeutics, Inc. Drug Profiles - (dabrafenib mesylate trametinib dimethyl sulfoxide) - AG-120 - ARN-5032 - ARQ-087 - BBI-503 - BGJ-398 - binimetinib - cabozantinib s-malate - CAP-7.1 - CC-90007 - CPI-613 - dasatinib - DKN-01 - elpamotide - evofosfamide - gemcitabine hydrochloride - Im-01 - KML-001 - MBPY-005 - melphalan - merestinib - MK-2206 - NUC-1031 - OCVC-01 - paclitaxel albumin bound - PAN-622 - pembrolizumab - ponatinib hydrochloride - porfimer sodium For more information visit http://www.researchandmarkets.com/research/6d...uct_cancer
PFE: 35.14 (-0.10), ARQL: 1.84 (+0.01), SPPI: 7.27 (-0.14), LLY: 85.57 (-2.30), GSK: 42.63 (-0.39), BMY: 68.87 (-1.10), MACK: 9.84 (-0.41), MRK: 58.67 (-0.33), AZN: 67.64 (-0.21), AGIO: 114.09 (-1.02), DCTH: 0.49 (-0.03), NVS: 103.71 (-2.41), ARRY: 6.73 (-0.06), CELGZ: 2.19 (+0.01), CXRX: 80.55 (+1.70), EXEL: 6.05 (+0.17)
Endometrial Cancer Therapeutics Pipeline Review, H1 2015 - 35 Companies & 48 Drug Profiles
M2 - Tue Jul 21, 3:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/psfwd9/endometrial) has announced the addition of the "Endometrial Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Endometrial Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometrial Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acceleron Pharma, Inc. - Aeterna Zentaris Inc. - Ariad Pharmaceuticals, Inc. - Arno Therapeutics, Inc. - ArQule, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - BioMarin Pharmaceutical Inc. - Boehringer Ingelheim GmbH - Critical Outcome Technologies Inc. - Daiichi Sankyo Company, Limited - Eisai Co., Ltd. - Esperance Pharmaceuticals, Inc. - Exelixis, Inc. - Farmsintez - Galena Biopharma, Inc. - Genentech, Inc. - Genmab A/S - GlaxoSmithKline Plc - Gradalis Inc. - ImmunoGen, Inc. - Incyte Corporation - Karyopharm Therapeutics, Inc. - Merck & Co., Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - Novartis AG - OncoHoldings, Inc. - Oncothyreon Inc. - Otsuka Holdings Co., Ltd. - Pharma Mar, S.A. - Puma Biotechnology, Inc. - Sanofi - Scancell Holdings Plc - Shenogen Pharma Group Ltd. Drug Profiles - (ponatinib hydrochloride ridaforolimus) - ???Pb-TCMC-Trastuzumab - AEZS-125 - afuresertib hydrochloride trametinib dimethyl sulfoxide - ARQ-092 - AV-203 - AZD-2014 - AZD-5363 - buparlisib hydrochloride - cabozantinib s-malate - cancer vaccine - Cell Therapy for Oncology - CLR-457 - COTI-2 - cridanimod - dalantercept - EP-200 - epacadostat - everolimus - FROST-450 - GALE-301 - GDC-0927 - GSK-2636771 - HO-3867 - HuMax-TF-ADC - INCB-54828 - lenvatinib - lurbinectedin - mirvetuximab soravtansine - MK-2206 - Modi-1 - Monoclonal Antibody to Inhibit L1CAM for Ovarian and Endometrial Cancer - neratinib - nintedanib - onapristone ER For more information visit http://www.researchandmarkets.com/research/ps...ndometrial
BMRN: 143.79 (-5.34), ARQL: 1.84 (+0.01), GALE: 1.74 (+0.01), EXEL: 6.05 (+0.17), XLRN: 30.79 (-1.79), INCY: 113.87 (-1.90), IMGN: 18.65 (-0.23), GSK: 42.63 (-0.39), ONTY: 3.62 (-0.04), AZN: 67.64 (-0.21), MRK: 58.67 (-0.33), AVEO: 1.68 (+0.06), PBYI: 99.72 (-3.54), KPTI: 23.26 (-0.72), NVS: 103.71 (-2.41)
Bristol-Myers: kidney drug win
at Investor's Business Daily - Mon Jul 20, 5:41PM CDT
The big pharma said that its Opdivo scored another win Mon. as a late-stage trial in kidney cancer was stopped early because it had already hit its endpoint. The trial compared Opdivo with everolimus, better known as Novartis' (NVS) Afinitor, in...
BMY: 68.87 (-1.10), EXEL: 6.05 (+0.17), NVS: 103.71 (-2.41)
Market Wrap: A Tech-Led Tick Higher
at The Street - Mon Jul 20, 3:45PM CDT
But energy and materials names, crude oil and gold all dropped.
HOG: 57.67 (+2.73), IBM: 163.07 (-10.15), UTX: 102.71 (-7.77), SUNE: 29.37 (-2.29), KKR: 24.20 (+0.44), VSLR: 15.85 (+0.10), VZ: 46.97 (-1.13), BHI: 60.64 (+1.18), EXEL: 6.05 (+0.17)
Exelixis' Meteroric Rise From the Ashes
Brian Orelli, The Motley Fool - Motley Fool - Mon Jul 20, 1:33PM CDT
Score one for tenacity. Exelixis is up almost 50% today after releasing positive results from its phase 3 trial, dubbed Meteor, testing its drug Cometriq in patients with kidney cancer. It's been a long road to get here. Like many...
EXEL: 6.05 (+0.17)
Bristol-Myers, Exelixis Drugs Score Vs. Kidney Cancer
at Investor's Business Daily - Mon Jul 20, 9:50AM CDT
Big pharma Bristol-Myers Squibb's (BMY) new drug Opdivo scored another win Monday, as a late-stage trial in kidney cancer was stopped early because it had already hit its endpoint. Small biotech Exelixis (EXEL) also reported success in a...
BMY: 68.87 (-1.10), NVS: 103.71 (-2.41), EXEL: 6.05 (+0.17)
Why Exelixis, Inc.'s Stock Skyrocketed Today
George Budwell, The Motley Fool - Motley Fool - Mon Jul 20, 9:46AM CDT
What's happening : Shares of Exelixis shot up by nearly 50% today on heavy volume after the company announced that its flagship cancer drug Cometriq (cabozantinib) met its primary endpoint of improving progression-free survival for renal cell...
EXEL: 6.05 (+0.17)
BUYINS.NET: EXEL SqueezeTrigger Price is $4.97. There is $285,011,222 That Short Sellers Still Need To Cover.
M2 - Mon Jul 20, 9:24AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring Exelixis Inc (NASDAQ:EXEL) in real time and just received an alert that EXEL is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 49309900 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $4.97. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
EXEL: 6.05 (+0.17)
Exelixis Scores Much-Needed Kidney Cancer Study Win to Boost Drug Sales
at The Street - Mon Jul 20, 6:01AM CDT
Exelixis plans to seek expanded approval for Cometriq in kidney cancer in early 2016.
NVS: 103.71 (-2.41), EXEL: 6.05 (+0.17)
Exelixis Announces Positive Top-Line Results from METEOR, the Phase 3 Pivotal Trial of Cabozantinib versus Everolimus in Patients with Metastatic Renal Cell Carcinoma
Business Wire - Mon Jul 20, 6:00AM CDT
--- Cabozantinib Reduced the Risk of Disease Progression or Death by 42%; Hazard Ratio = 0.58, (p < 0.0001) Compared to Everolimus -
EXEL: 6.05 (+0.17)
3 Biotech Stocks 50% (or More) Off Their 5-Year Highs That Could Double
Sean Williams, The Motley Fool - Motley Fool - Thu Jul 16, 8:01AM CDT
Source: Food and Drug Administration via Facebook. If there is such a thing as a poster child for volatility in the stock market, the biotech sector would likely take top honors. Biotech stocks are unique. While stocks in other sectors are...
THLD: 4.26 (-0.01), XOMA: 4.39 (-0.13), EXEL: 6.05 (+0.17)
Exelixis Appoints Chris Senner as Executive Vice President and Chief Financial Officer
Business Wire - Wed Jul 15, 7:00PM CDT
Exelixis, Inc. (NASDAQ:EXEL) today announced the appointment of Christopher J. Senner as Executive Vice President and Chief Financial Officer. Mr. Senner has nearly 25 years of experience in biopharmaceutical finance, including deep expertise in global financial operations and controls, strategic planning and analysis, supply chain finance and business development. He joins Exelixis after five years at Gilead Sciences, where he served as Vice President, Corporate Finance. He previously spent eighteen years at Wyeth in a variety of financial roles with increasing responsibility for many of the company's divisions and regions. He joins Exelixis in advance of several potentially transformational milestones anticipated this year, including top-line results from the METEOR phase 3 pivotal trial and the potential U.S. and EU regulatory approvals of cobimetinib, a compound discovered by Exelixis and then licensed to Genentech for further development and commercialization.
EXEL: 6.05 (+0.17)
